CDKN2A and breast carcinoma: For instance, in an in vitro study on breast cancer cell lines, the sensitivity to the CDK4/6 inhibitor palbociclib (PD 0332991) was mainly limited to the luminal cell lines with a microarray signature of high cyclin D1, high RB and low CDKN2A; meanwhile cyclin D3 was not part of the sensitivity signature [24].